Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “Visages”

BACKGROUND: IgG replacement therapy (IgRT) in primary immunodeficiencies (PID) is a lifelong treatment which may be administered intravenously (IVIg) or subcutaneously (SCIg), at hospital or at home. The objective of the VISAGE study was to investigate if route and/or place for IgRT impact patients’...

Descripción completa

Detalles Bibliográficos
Autores principales: Bienvenu, B., Cozon, G., Hoarau, C., Pasquet, M., Cherin, P., Clerson, P., Hachulla, E., Crave, J. C., Delain, J. C., Jaussaud, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917986/
https://www.ncbi.nlm.nih.gov/pubmed/27334100
http://dx.doi.org/10.1186/s13023-016-0452-9

Ejemplares similares

Ejemplares similares